Headquartered in the UK and employing over 800 people, Oxford Biomedica (LSE: OXB) is a fully integrated gene and cell therapy group and CDMO focused on developing life-changing treatments for serious diseases. It is developing product candidates in the areas of oncology, ophthalmology and CNS disorders, and is seen as a leading light in the C> world
OXB’s market cap had dwindled to c £30m and it could no longer raise sufficient capital to pursue its manufacturing or product development goals. The shareholders were confident in the technology and capability but recognised the need to strategically review the senior leadership in order to drive the company forward.
How our approach made a difference:
Following extensive and continuous Board Review and ELT skills analysis, The RSA Group ran two CFO searches over time which supported first the company’s recovery and refinancing, and then its growth. Oxford Biomedica now has a market cap of c. £750m and generates revenues of >£95m from its four facilities.